Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Editas

This page shows the latest Editas news and features for those working in and with pharma, biotech and healthcare.

Allergan and Editas claim a CRISPR first in inherited blindness study

Allergan and Editas claim a CRISPR first in inherited blindness study

Allergan and Editas Medicine have made history after scientists used a CRISPR treatment developed by the partners to edit cells inside the human body. ... treatment. Allergan and Editas plan to treat a further 18 LCA10 patients with EDIT-101, to evaluate

Latest news

  • GSK joins forces with Doudna’s CRISPR lab GSK joins forces with Doudna’s CRISPR lab

    The first ever FDA-approved clinical trial of an in vivo CRISPR-based therapy is expected to get under way very soon; Editas and Allergan plan to begin the trial of

  • Trial dents confidence in Sangamo’s gene-editing tech Trial dents confidence in Sangamo’s gene-editing tech

    Companies developing other gene-editing technologies, such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine, also saw their shares close down, suggesting a knee-jerk reaction in the sell-off.

  • Editas CEO exits the CRISPR firm ahead of first clinical trial Editas CEO exits the CRISPR firm ahead of first clinical trial

    Shares in company and competitors sink. Gene-editing specialist Editas Medicine will have to start its first CRISPR clinical trial without the direction of president and CEO Katrine Bosley, who has ... Editas has named board member Cynthia Collins as

  • Sangamo’s first gene-editing trial doesn’t convince investors Sangamo’s first gene-editing trial doesn’t convince investors

    But companies developing other gene-editing technologies, such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine, also saw their shares close down which might suggest an element of panic in the

  • Allergan builds on gene editing deal Allergan builds on gene editing deal

    The Allergan team is excited to work with colleagues at Editas Medicine to develop EDIT-101 and potentially deliver a transformative medicine for LCA10 patients.". ... These developments have caused the shares of leaders in the field, CRISPR Therapeutics,

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Editas, and the failure of Sangamo Therapeutics’ rival zinc-finger nucleases (ZFNs) platform. ... Editas, CRISPR, Sangamo, Cellectis/Allogene and their peers to take the slow road to proving that gene- editing can deliver safe and effective

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    There has been a lot of chatter about developing the tool for therapeutic use, and some specialised pharma companies such as Editas already have candidates in the pipeline. ... Editas Medicine and partner Allergan plan to initiate a phase 1/2 clinical

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other

  • Deal Watch May 2016 Deal Watch May 2016

    This follows the $94m IPO of Editas Medicine in February this year.

  • Deal Watch October 2015 Deal Watch October 2015

    companies. Other biotechs exploiting the CRISPR/Cas-9 technology for the development of therapeutics include Editas Medicine, Intellia Therapeutics and Caribou Biosciences; both Novartis and AstraZeneca have already developed collaborations in

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • New hires at Abbott, Kite and Arrakis Therapeutics New hires at Abbott, Kite and Arrakis Therapeutics

    Most recently, Bosley served as the chief executive officer of Editas Medicine, and previously worked as CEO of Avila Therapeutics until its acquisition by Celgene.

  • Editas Medicine names James Mullen as chairman Editas Medicine names James Mullen as chairman

    He has previously served as CEO of Patheon. Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors. ... Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned

  • Editas Medicine adds to its board of directors Editas Medicine adds to its board of directors

    Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who will also serve on the board's audit committee. ... She said: “I am honoured to join Editas Medicine’s board of directors. “

  • Editas Medicine adds to board of directors Editas Medicine adds to board of directors

    Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... Katrine Bosley, Editas Medicine's president and chief executive officer, said: “I am

More from appointments
Approximately 3 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....

Quick links